• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YANG Ying,SUN Ru,CAO Yanhua.Research progress on the effect of selective COX-2 inhibitors on cardiovascular diseases[J].Journal Of Pharmaceutical Research,2016,35(1):41-45[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 5929times   Download 5422次 QR Code for this article
Scan with your phone!
选择性环氧化酶-2抑制剂对心血管影响的研究进展
杨鹰1,孙茹2,曹艳花2
Font:Larger+|Default|Smaller-
(1.中国人民解放军第四〇一医院高压氧科,山东 青岛 266071;2.山东大学附属省立医院药剂科,山东 济南 250021)
摘要:
目的 综述选择性环氧化酶-2抑制剂在心血管方面的安全性及其作用机制。方法 通过查阅国内外相关文献,分别比较归纳了不同选择性环氧化酶-2抑制剂引发心血管事件的风险性,并总结了罗非昔布、塞来昔布等对心血管的作用机制。结果 对选择性环氧化酶-2抑制剂引发心血管不良反应的研究进展进行了比较全面的总结。结论 不同选择性环氧化酶-2抑制剂在心血管安全性方面有明显差别,比较几种昔布类药物,塞来昔布相对安全,与小剂量阿司匹林联合服用可降低心血管风险性。
关键词:  环氧化酶-2  心血管  塞来昔布  罗非昔布
DOI:
基金项目:北京市科委首都市民健康项目培育科研基金资助项目(No.Z12110200750000)
Research progress on the effect of selective COX-2 inhibitors on cardiovascular diseases
YANG Ying1,SUN Ru2,CAO Yanhua2
(1.No.401 Hospital Affiliated to Chinese People's Liberation Army,Qingdao 266071,China;2.Provincial Hospital affiliated to Shandong University,Jinan 250021,China)
Abstract:
Objective To review the effect of selective COX-2 inhibitors on cardiovascular diseases and their mechanisms.Methods By consulting related references,the risk of cardiovascular events caused by different selective COX-2 inhibitors was compared, and the effect mechanisms of rofecoxib and celecoxib on cardiovascular system were summarized.Results The research progress of selective COX-2 inhibitors and adverse cardiovascular events were comprehensively summarized.Conclusion A different risk profile for COX-2 inhibitors had emerged.Compared to rofecoxib and other coxibs,celecoxib was relatively safe.Receiving celecoxib with low-dose aspirin was recommended to exhibit lower cardiovascular risk.
Key words:  COX-2  Cardiovascular disease  Celecoxib  Rofecoxib
Today's Visits:438    Total Visits:2383115
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.